AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-13 and is reviewed periodically as new material appears.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Adam Baldwin (born February 27, 1962) is an American actor. He made his film debut in My Bodyguard (1980) and later appeared in films including Full Metal Jacket (1987), Predator 2 (1990), Independence Day (1996), The Patriot (2000), and Serenity (2005). On television, he is known for playing Jayne Cobb in Firefly, John Casey in Chuck, and Mike Slattery in The Last Ship. He has also worked as a voice actor, including as Superman in Superman: Doomsday (2007) and Dutch in Halo 3: ODST (2009).
== Drug interaction == Pioglitazone/metformin may interact with furosemide, nifedipine, cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) and certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control (e.g., thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid).
PLP plays a role in the conversion of levodopa into dopamine, facilitates the conversion of the excitatory neurotransmitter glutamate to the inhibitory neurotransmitter GABA, and allows SAM to be decarboxylated to form propylamine, which is a precursor to polyamines.
where e, f, g and h are the tangent lengths at A, B, C and D respectively. Combining the first equality with a previous property, the "vertex centroid" of the tangential quadrilateral coincides with the incenter if and only if the incenter is the midpoint of the line segment connecting the midpoints of the diagonals. If a four-bar linkage is made in the form of a tangential quadrilateral, then it will remain tangential no matter how the linkage is flexed, provided the quadrilateral remains convex. (Thus, for example, if a square is deformed into a rhombus it remains tangential, though to a smaller incircle). If one side is held in a fixed position, then as the quadrilateral is flexed, the incenter traces out a circle of radius
=== Neurotransmitter release is calcium-dependent === Neurotransmitter release is dependent on an external supply of Ca2+ ions which enter axon terminals via voltage-gated calcium channels. Vesicular fusion with the terminal membrane and release of the neurotransmitter is caused by the generation of Ca2+ gradients induced by incoming action potentials. The Ca2+ ions cause the mobilization of newly synthesized vesicles from a reserve pool to undergo this membrane fusion. This mechanism of action was discovered in squid giant axons. Lowering intracellular Ca2+ ions provides a direct inhibitory effect on neurotransmitter release. After release of the neurotransmitter occurs, vesicular membranes are recycled to their origins of production. Calcium ion channels can vary depending on the location of incidence. For example, the channels at an axon terminal differ from the typical calcium channels of a cell body (whether neural or not). Even at axon terminals, calcium ion channel types can vary, as is the case with P-type calcium channels located at the neuromuscular junction.
Sources: en.wikipedia.org
where i is each one of the gases that adsorb. Note: 1) To choose between the Langmuir and Freundlich equations, the enthalpies of adsorption must be investigated. While the Langmuir model assumes that the energy of adsorption remains constant with surface occupancy, the Freundlich equation is derived with the assumption that the heat of adsorption continually decrease as the binding sites are occupied. The choice of the model based on best fitting of the data is a common misconception. 2) The use of the linearized form of the Langmuir model is no longer common practice. Advances in computational power allowed for nonlinear regression to be performed quickly and with higher confidence since no data transformation is required.
The policy states the goal of its creation is to assist employees of the county in their daily operations to boost efficiency and productivity in a responsible, secure, and uniform manner across the county's many taskforces. With its publication, Alameda County became one of several counties across the nation willing to publicly disclose their AI policy, allowing any curious person to read the full policy online. In order to reap the benefits that GenAI can offer as a tool for county business, it is required per the policy, that any GenAI software is to be approved by the county's Information Technology Department. The policy is meant to supplement, not replace, statewide laws and regulations pertaining to the use of AI.
Such metabolic profiles can provide a complete overview of individual metabolite or pathway alterations, providing a more realistic depiction of disease phenotypes. This approach can then be applied to the prediction of response to a pharmaceutical compound by patients with a particular metabolic profile. Pharmacometabolomic analyses of drug response are often coupled or followed up with pharmacogenetics studies. Pharmacogenetics focuses on the identification of genetic variations (e.g. single-nucleotide polymorphisms) within patients that may contribute to altered drug responses and overall outcome of a certain treatment. The results of pharmacometabolomics analyses can act to "inform" or "direct" pharmacogenetic analyses by correlating aberrant metabolite concentrations or metabolic pathways to potential alterations at the genetic level. This concept has been established with two seminal publications from studies of antidepressants serotonin reuptake inhibitors where metabolic signatures were able to define pathway implicated in response to the antidepressant and that lead to identification of genetic variants within a key gene within highlighted pathway as being implicated in variation in response. These genetic variants were not identified through genetic analysis alone and hence illustrated how metabolomics can guide and inform genetic data.
Russian and US diplomats said their diplomatic relations were worse than during the 1962 Cuban Missile Crisis. Kremlin spokesperson Dmitry Peskov told a reporter of a Russian state-run television network, "We are taking steady steps towards the Cold War ... All the attributes of the Cold War with the direct confrontation are returning." Polish retired general and defense analyst Stanisław Koziej wrote in 2024 that "A second cold war against the West is intensifying in Europe. Russia launched it by annexing Crimea in 2014 and following up with a full-scale armed invasion of Ukraine". He said that "this cold war is similar to the first one" but differs in that "it employs a bigger toolbox of activities that are often referred to as 'hybrid' or in the gray zone". Koziej highlighted recent Russian hybrid warfare operations against eastern NATO states, including sabotage, cyberattacks, airspace violations, espionage, weaponized migration, disinformation operations and nuclear blackmail. Sabine Siebold, Senior European Security correspondent for Reuters, also cited Russian hybrid warfare and NATO troop build-ups as evidence that there was a "new Cold War" between Russia and NATO. She added, "in some ways, it even feels hotter than the Cold War in the 80s. This time we have a war raging on European territory involving Russian forces and Western weapons and many arms control treaties that were in place in the 80s have collapsed in the meantime".
=== Patenting === In the U.S., efforts into creating a chimeric entity appeared to be legal when the topic first came up. Developmental biologist Stuart Newman, a professor at New York Medical College in Valhalla, N.Y., applied for a patent on a human-animal chimera in 1997 as a challenge to the U.S. Patent and Trademark Office and the U.S. Congress, motivated by his moral and scientific opposition to the notion that living things can be patented at all. Prior legal precedent had established that genetically engineered entities, in general, could be patented, even if they were based on beings occurring in nature. After a seven-year process, Newman's patent finally received a flat rejection. The legal process had created a paper trail of arguments, giving Newman what he claimed was a victory. The Washington Post ran an article on the controversy that stated that it had raised "profound questions about the differences—and similarities—between humans and other animals, and the limits of treating animals as property."
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.